Tardive dyskinesia (TD) is an iatrogenic disorder observed in B20-30% of schizophrenia patients on long-term treatment with typical antipsychotic drugs. CYP1A2 is involved in the metabolism of atypical antipsychotic drugs such as clozapine and olanzapine. It is not directly involved in the metabolism of typical antipsychotic drugs, but gains importance when the schizophrenia patients are under long-term chronic treatment, acting as a low-affinity high-capacity metabolizing enzyme. In this study, we have completely sequenced the coding region to ascertain the presence of common coding polymorphisms and their role if any in susceptibility to TD and schizophrenia. Four previously reported polymorphisms, CYP1A2*1F (intron A), rs2472304 & rs3743484 (intron D) and rs2470890 (CYP1A2 1545 C4T) in exon 7 were identified. We further investigated whether the CYP1A2 1545 C4T polymorphism has any role to play in susceptibility to TD and in schizophrenia per se. Association of this single nucleotide polymorphism with TD (P ¼ 0.03) and schizophrenia (P ¼ 0.04) was observed, but was rendered insignificant after corrections for multiple comparisons.
Introduction
Schizophrenia is a severe debilitating neuropsychiatric disorder with a lifetime prevalence of approximately 1%. Tardive dyskinesia (TD) is an iatrogenic disorder developing in a subset of these patients chronically treated with typical antipsychotic drugs. The etiology of TD is unknown; however, its occurrence in a subset of patients, familial clustering and concordance rates among twins suggest a possible influence of genetic factors on this complex phenotype. 1, 2 Advancing age, duration of treatment, female gender and organic brain abnormalities are other well-known risk factors. 3, 4 No singular hypothesis proposed so far can explain the pathogenesis of TD. One of the most accepted is the dopamine supersensitivity hypothesis, according to which, the chronic blockade of the post-synaptic D2 receptors by typical antipsychotic drugs leads to a compensatory increase in the D2 receptor density in all dopaminergic pathways. Withdrawal or discontinuation of drugs would lead to the dissociation of drug molecules from the receptors. This would allow the natural ligand dopamine to bind to its receptor. Owing to an increase in the number of receptors, specifically in the extrapyramidal motor system, dopamine binding would lead to hyperactivity of dopaminergic neurons manifested as involuntary dyskinetic movements. However, there are several lacunae in this hypothesis and several others such as gamma amino butyric acid insufficiency, dysfunction of the serotonergic system and a free radical hypothesis have been proposed (for details, see Andreassen and Jorgensen, 5 Lohr et al. 6 and Casey 7 ). Based on these hypotheses, several genes from dopaminergic, serotonergic and oxidative stress pathways have been investigated for their possible contribution to susceptibility to TD (for review, see Basile et al. 8 ). With the possible exception of the DRD3 ser9gly polymorphism, which has been supported by both pooled and metaanalyses, 9 no other polymorphism has been consistently implicated in the genesis of TD. As the basic mechanism proposed for TD development is chronic blockade of the receptors owing to high affinity of typical antipsychotics for dopamine receptors, any variation in the receptor affinity to the particular drugs owing to polymorphisms (e.g. DRD3 ser9gly) could lead to a predisposition to TD. In addition, the amount/number of drug molecules available at synapse may also play a critical role. The therapeutic levels of the drug in plasma (and at synapse) are influenced by several factors, including absorption from the site of administration, distribution in the body and rate of elimination from blood circulation, the last being a major factor. Thus, along with the above-mentioned pathways, the genes involved in the metabolism of these drugs may also influence the development of this iatrogenic disorder. CYP3A4 (B50%), CYP2D6 (B30%), CYP1A2, CYP2C9, CYP2C19 and CYP2E1 are together responsible for the elimination of a majority of antipsychotic drugs. 10 As in the case of dopamine receptors, genetic polymorphism/ variations in these genes could control/modulate the bioavailability and thus binding of drugs to the receptors. Considerable inter-individual and inter-ethnic variation in the extent of drug metabolism has been observed. These variations in drug clearance have been attributed to Association of CYP1A2 1545C4T polymorphism with TD and schizophrenia
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polymorphisms that lead to poor metabolizer/low inducible phenotype, and thus lead to higher plasma level and delayed clearance of drug from the body. Such polymorphisms may partially explain the development of side effects such as TD in only a subset of patients.
Hence, we undertook to analyze polymorphisms/variations in the cytochrome P450 1A2 gene (CYP1A2; 15q22-qter; MIM #124060), which is involved in the metabolism of atypical antipsychotics such as clozapine and olanzapine. It is not directly involved in the metabolism of typical antipsychotic drugs, but gains importance when the schizophrenia patients are under long-term treatment. Under normal circumstances, CYP2D6, considered as a highaffinity low-capacity metabolizer, is involved in the clearance of typical antipsychotic drugs. However, under saturation condition, CYP1A2, a low-affinity high-capacity metabolizer, gains importance. 11 Additionally, CYP1A2 is induced by polycyclic aromatic hydrocarbons present in cigarette smoke and the reported alleles (marked in bold here) CYP1A2*1C (À3858G4A) and CYP1A2*1F (À163 A4C) lead to low induction in subjects who are smokers, thus influencing the bioavailability of antipsychotic drugs.
11-13 Previously, we had investigated the contribution of these two polymorphisms in the susceptibility to TD and did not observe any significant association with TD but observed an increased severity of TD in subjects carrying the A allele of the CYP1A2*1C polymorphism. 14 We had also investigated four other reported amino-acid substitutions in the coding region, but these were found to be monomorphic in our population. The study has now been extended to ascertain the presence of other common coding polymorphisms by completely sequencing the exons/exon-intron boundaries of CYP1A2 gene and their role in TD susceptibility and schizophrenia per se.
Results
We sequenced the coding region of the CYP1A2 gene completely. No nonsynonymous polymorphisms were identified, but four previously reported polymorphisms were observed (Table 1) . Three polymorphisms are present in the intronic region (CYP1A2*1F and rs2472304, rs3743484) and CYP1A2 1545 C4T (rs2470890) is a synonymous coding polymorphism. The frequencies of these polymorphisms are similar to those reported in the single nucleotide polymorphism database and are in Hardy-Weinberg equilibrium (HWE) in the present samples. The common haplotypes prevalent in the population and the linkage disequilibrium (LD) between the markers are listed in Tables 2 and 3 .
The allele frequencies for CYP1A2 1545 C4T in the control population is C ¼ 0.77, T ¼ 0.23 (PIC ¼ 0.323). The distribution of the genotypes in the control population was in HWE (w 2 ¼ 2.85, df ¼ 1, P ¼ 0.09). The observed genotypic frequencies did not deviate from those expected under HWE for subjects with and without TD and those on different drug regimens (P40.05). There was no statistically significant difference in the distribution of genotypic frequencies between the entire TD-Y vs TD-N group. A difference in the distribution of genotypic frequency was observed (TT þ CT vs CC, P ¼ 0.03; odds ratio ¼ 2.940; 95% confidence interval (CI): 1.136-7.609) for subjects receiving only typical antipsychotics, which became insignificant after multiple correction (Bonferroni corrected P ¼ 0.12). The mean abnormal involuntary movement scale (AIMS) score was higher, although statistically insignificant, for individuals carrying one or two copies of the T allele (Table 4) . No difference in the allelic, genotypic distribution and mean AIMS score across the two genotypic categories was observed for the subjects who had received only atypical drugs. We also investigated whether the above polymorphism is a risk factor for the development of schizophrenia (Table 5) . Genotypic as well as allelic distribution of CYP1A2 1545C4T was statistically significant (w 2 ¼ 6.38, df ¼ 2, P ¼ 0.04; w 2 ¼ 5.71, df ¼ 1, P ¼ 0.02, respectively). Previously, we investigated the association of CYP1A2*1C and CY-P1A2*1F with schizophrenia and we observed a trend of association of only CYP1A2*1F (À163C4A) with schizophrenia and found the C allele to be over-represented in the control population (odds ratio ¼ 0.756; 95% CI: 0.596-0.958), suggesting that it is protective. Haplotypes were constructed between CYP1A2*1F and CYP1A2 1545C4T polymorphisms using PHASE version 2.0.2 ( Table 6 ). As CYP1A2*1C is not polymorphic, it was not included in the haplotype construction. A nominally significant haplotypic association was observed with the two markers (global 
Discussion
Considerable interindividual and interethnic variation in the efficacy/toxicity of drugs has been observed. Understanding the genetic basis of such variability is a thrust area in the post human genome-sequencing era. TD is one such complex phenotype developing as a side effect in B20-30% of chronic schizophrenia patients treated with typical antipsychotic drugs. The phenotype of TD is relatively well defined and the severity of the features can be measured on a standardized scale. Along with genes from neurotransmitter pathways, the genes involved in drug metabolism have been extensively investigated. CYP1A2 is not directly involved in the metabolism of typical antipsychotic drugs, but gains importance when the primary metabolizer CYP2D6 is saturated. Although upto 30-fold variation in the expression of CYP1A2 gene has been observed, 15 no polymorphism/s explaining this level of variability have been found. We previously investigated two SNPs, CY-P1A2*1C (À3858G4A) in the 3-methylcholanthrene element and CYP1A2*1F (A4C) located in the first intron. Both these variants lead to lesser inducibility among smokers (A allele of CYP1A2*1C; C allele of CYP1A2*1F 12, 13 ). We did not observe any association of these two markers with TD.
14 To rule out the contribution of other reported polymorphisms from the coding region of this gene to the differential activity and thus to the development of TD, we genotyped four reported nonsynonymous amino-acid substitutions 16 but these were found to be monomorphic in our population.
14 In order to screen the coding region for any novel polymorphism, we sequenced the seven exons of CYP1A2 gene. Nonsynonymous polymorphisms were not observed in the exons; however, a previously reported synonymous polymorphism in exon 7 CYP1A2 1545 C4T (N515 rs2470890) along with three other intronic polymorphisms were observed. The frequency of this polymorphism in the control population was similar to that reported in the dbSNP database (C ¼ 0.735, T ¼ 0.265). We further investigated whether CYP1A2 1545 C4T polymorphism had any role to play in susceptibility to TD and observed a significant excess of the T allele in individuals who were TD positive and had received only typical drugs. However, following multiple corrections, the observed association was not significant. Synonymous substitutions have been reported to affect the mRNA stability, but in the absence of any experimental evidence it is difficult to put forward a plausible hypothesis. Also, this observation has been made in a relatively small sample and could be owing to a type II error. Replication in a large sample set and in other populations is essential.
Lesser propensity for the development of TD by atypical antipsychotic usage has been reported. 17 Previously, 80% occupancy of D2 receptors has been associated with the development of extrapyramidal symptoms. Although at lesser dosage of risperidone (2-8 mg) only 64-80% D2 receptor occupancy is observed, at higher doses (12 mg) more than 80% occupancy was observed. Similar observation has been made for other atypical antipsychotic drugs such as olanzapine. 18 In our study, the atypical drugs that were predominantly prescribed were risperidone and olanzapine. CYP1A2 has not been reported to metabolize risperidone; however, a minor role of this gene has been ascribed in case of olanzapine metabolism. 19 Thus, our observation of lack of significant association of CYP1A2 1545C4T (this study), CYP1A2*1C or CYP1A2*1F 14 with the development of TD seems appropriate. Further, the only variability in the metabolism by CYP1A2 has been associated with the induction by smoking. In our study, the prevalence of smoking was low (B23%) and therefore there would be low/no contribution to the variability of metabolism by CYP1A2. Thus, this observation of lack of association of CYP1A2 gene polymorphisms as well as of comparable severity across the genotypic categories of all the three SNPs tested, suggests a negligible role of this gene in the development of TD among north Indian subjects administered with only atypical drugs.
We also observed a nominally significant allelic and genotypic association of this polymorphism with schizophrenia. Previously, we had observed a similar association of CYP1A2*1F C4A polymorphism and found the C allele to be protective.
14 Although CYP1A2 by itself has never been implicated in pathogenesis of schizophrenia, the neighboring loci (15q13-15) have all been implicated. [20] [21] [22] [23] CYP1A2 (15q21) is located in the vicinity of nicotinic receptors CHRNA3, CHRNA5 and CHRNB4, localized at 15q24. CYP1A2 mRNA has been detected in the rat brain (cortex, cerebellum, brain stem, thalamus, hippocampus and striatum 24 ). Its presence in brain tissues probably plays a role in protecting the brain from xenobiotics and/or other unknown compounds and differential activity of the gene in vivo may be responsible for differential susceptibility. Alternately, it is also likely that this SNP is in LD with another putative candidate gene for schizophrenia. We observed a significant excess of the T allele in schizophrenia patients, suggesting a probable role in schizophrenia pathogenesis (odds ratio ¼ 1.439; 95% CI: 1.06-1.94). However, two marker haplotype reconstruction with CYP1A2*1F, the haplotype containing the T allele, did not show any statistical significance. The C-C haplotype is significantly associated and appears to be protective (odds ratio ¼ 0.749; 95% CI: 0.58-0.96), but the observation was not significant following Boneferroni correction. Considering the moderately large sample size and the trend for replication of association, it still might be of some importance. The C allele of CYP1A2*1F earlier reported to be protective, is in complete LD with the C allele of CYP1A2 1545 C4T which is located B6 kb apart. If we look at the number of haplotypes that have been observed in the control population (Table 3) , the A allele of CYP1A2*1F appears in combination with both C and T, but the C allele of CYP1A2*1F appears only with the C of CYP1A2 1545 C4T.
It is possible that the C allele of CYP1A2*1F originated on the chromosome bearing the A-C haplotype leading to C-C haplotype, which increased in frequency owing to selection or some other stochastic processes. The A-T haplotype could have arisen following mutation at the C allele of CYP1A2 1545C4T in the A-C haplotype ( Figure 1) . As mentioned earlier, the CYP1A2 gene is flanked by gene/loci that have been implicated in schizophrenia pathogenesis and the C-C haplotype might be a part of a larger hapblock which confers susceptibility to schizophrenia. Thus, it seems unlikely that the CYP1A2 1545C4T polymorphism by itself contributes to the pathogenesis of schizophrenia, but the trend for replication of the association previously observed with CYP1A2*1F suggests that this locus may contribute to disease susceptibility in north Indian population.
Materials and methods

Subjects
Recruitment of the patients occurred at the Department of Psychiatry, RML Hospital, New Delhi. Patients with schizophrenia (n ¼ 335) diagnosed according to diagnostic and statistical manual of mental disorders (DSM) IV criteria were included in this retrospective cross-sectional case-control study. Of the 335 patients with schizophrenia, 96 (28.66%) were diagnosed with TD based on the AIMS. 25 Mean AIMS score of the subjects with TD (denoted TD-Y) was 6 14 Age-, sex-and ethnicity-matched healthy individuals (n ¼ 270) were recruited from the collaborating hospitals and the University Health Center. The controls and their families had no previous history of any neuropsychiatric disorder. Ethical committee clearance from the respective institutes was obtained.
Genetic analysis
Genomic DNA was isolated from whole blood using the conventional phenol chloroform extraction method. For SNP discovery all the seven exons and exon-intron boundaries from 15 to 20 unrelated healthy individuals were polymerase chain reaction (PCR) amplified and sequenced (ABI 3700 sequencer, Applied Biosystems Inc., Foster City, USA) using a commercial facility. The validation of SNPs detected by sequencing was carried out using PCRrestriction fragment length polymorphism (Table 1) . Briefly, the PCR was performed in a total reaction volume of 20 ml containing 100 ng of DNA template, 200 mM deoxynucleotide triphosphates, 5 pmol of each primer, 1.5 mM MgCl 2, 0.5 U of Taq polymerase (Biotools, B & M Labs, S.A., Spain) and 1 Â PCR reaction buffer. For digestion, PCR products were incubated with 1 U of restriction enzyme overnight. Depending on the size, the digestion products were resolved on a 2.5-3.5% agarose or 12% polyacrylamide gel and visualized using ethidium bromide. Samples with known genotypes confirmed by sequencing were included in each set of genotype assays to ensure accuracy. Some samples could not be genotyped because of failure of repeated PCRs owing to unknown technical reasons.
Statistical analysis
Frequencies of each of the SNPs were calculated for healthy volunteers. Deviations from Hardy-Weinberg expectations were calculated for cases and controls separately. Genetic associations were evaluated using the w 2 test and CLUMP software was used for contingency tables with small cell count. 26 All statistical tests utilized SPSS version 11.0 software. Mean AIMS scores were compared between each of the genotypic classes using analysis of covariance (ANCOVA), with age as a covariate. Levene test for homogeneity of variance was carried out to check the assumption of equal variance among each genotypic class, and normal distribution of genotypic categories was tested using Kolmogrov-Smirnov Z test. In case of violation of any of the assumptions of ANCOVA, the nonparametric KruskalWallis H test was performed. Haplotypes were reconstructed using PHASE version 2.0.2. 
